Trial Profile
Phase III, Parallel-group, Placebo Controlled, Double-blind, Randomized, Multicenter International Study to Investigate the Safety and Efficacy of Propionyl-L-carnitine Hydrochloride (ST261) Modified Release Tablets in Patients Affected by Mild Ulcerative Colitis under Oral Stable Treatment
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Propionyl carnitine (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Sponsors sigma-tau SpA
- 07 Apr 2022 This trial has been completed in Netherlands and Slovakia (13 Aug 2013), according to European Clinical Trials Database record.
- 09 Apr 2014 According to ClinicalTrials.gov record, status changed from recruiting to discontinued.
- 21 Apr 2012 Planned number of patients changed from 400 to 444 as reported by European Clinical Trials Database.